NASDAQ:ALNY

Alnylam Pharmaceuticals, Inc Earning Date

USA |NASDAQ |USD

ALNY Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-1.57 $-1.61 $-2.18
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $218.54M $220.55M $125.85M

Alnylam Pharmaceuticals, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

ALNY Earnings Date & History Chart

ALNY Earnings & Revenue Forecast

ALNY Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 17 $-1.59 $-2.49 $-0.84
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 19 $-6.35 $-7.82 $-5.16
Dec 2022 18 $-4.10 $-6.65 $-1.69

ALNY Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-1.59 $-1.46 $-1.45
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-6.40 $-6.39 $-6.37
Dec 2022 0 / 1 $-3.73 $-3.67 $-3.60

ALNY Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 17 $238.92M $214.40M $263.80M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 21 $852.70M $823.60M $902.00M
Dec 2022 19 $1.29B $1.10B $1.50B

ALNY Earnings Date & Revenue History

ALNY Earnings History

|
Show More
Show More

ALNY Revenue History

|
Show More
Show More

Alnylam Pharmaceuticals, Inc Next Earnings Date & Report

ALNY Next Earnings Date & Report Preview: Sep 2021 (FQ)

ALNY's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 17 analysts, the average EPS estimation for Alnylam Pharmaceuticals, Inc's next quarterly earnings is $-1.57, with a low EPS estimation of $-2.01, and a high estimation of $-1.25.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $-1.57, the last 2 month trend is $-1.57, and the 3 month trend is $-1.57.

Based on 16 analysts, the average revenue estimation is $218.54M, with a low revenue estimation of $202.06M, and a high estimation of $240.10M.

Alnylam Pharmaceuticals, Inc Previous Earnings Dates & Reports

ALNY Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Alnylam Pharmaceuticals, Inc's previous earnings date was Aug 3, 2021 for its fiscal quarter ended Jun 30, 2021.

ALNY's earnings per share (EPS) was $-1.61, beating the consensus analysts forecast of $-1.63 by 1.37%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -5.85%, and lower than the same period a year before (Jun 2020) by 3.21%.

Revenues were $220.55M, better than the forecast of $220.55M by 0.00%, up by 24.21% from the previous quarter , and up by 112.15% from the same period last year.

The company reported a net income of $-189.56M.

Free cash flow for the quarter was $-133.10M , compared to $-252.84M last quarter and $-151.99M a year before.

ALNY ended the quarter with $761.07M in total debt, an increase of 46.78% compared to the previous quarter, and an increase of 141.56% compared to the same quarter a year before.

ALNY Previous Earnings Date & Report Recap: Dec 2020 (FY)

Alnylam Pharmaceuticals, Inc's previous annual earnings date was Feb 11, 2021 for its fiscal year ended Dec 31, 2020.

ALNY's earnings per share (EPS) was $-7.45, missing the consensus analysts forecast of $-7.18 by 3.76% , and higher than the previous year's EPS (Dec 2019) by -8.48%.

Revenues were $492.85M, better than the forecast of $476.72M by 3.38%, and up by 124.28% from previous year's revenue.

The company reported a net income of $-858.28M.

Alnylam Pharmaceuticals, Inc reported a free cash flow of $-685.32M for its fiscal year, compared to $-418.58M a year ago.

The company ended the fiscal year with $228.15M in total debt, a decrease of -24.91% compared to the previous year.